Aloop Therapeutics ApS: Financial statements 2023
CVR: 43257498
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Aloop Therapeutics ApS (CVR 43257498) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -9,058,291 and a net result of DKK -8,808,915. Equity in the 2023 report amounted to DKK 32,022,337. The solvency ratio was 93.5%. The company had 8 employees in the financial year.
- Gross Profit
- DKK -9,058,291
- Profit/Loss
- DKK -8,808,915
- Equity
- DKK 32,022,337
- Total Assets
- DKK 34,250,091
- Employees
- 8
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of July 4, 2023, Camilla Petrycer Hansen has joined the board of directors of Aloop Therapeutics ApS.
As of July 4, 2023, Jens Bo Rode Hansen has left the board of directors of Aloop Therapeutics ApS.
As of July 3, 2023, Camilla Petrycer Hansen has left the board of directors of Aloop Therapeutics ApS.
Aloop Therapeutics ApS has published its interim report for the period May 6, 2022 to December 31, 2022.
About Aloop Therapeutics ApS
Aloop Therapeutics ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2022. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Rodolphe Clerval. The company is owned by Coave Therapeutics. The company has 6 employees (2024). In 2025, the company reported a gross profit of DKK -274,227 and a net result of DKK -69,892 compared with DKK -1,295,153 the year before. Equity in the 2025 report amounted to DKK 30,657,300.
